Assessment of the efficacy of targeted PDA-66 therapy in a PC-3 Prostate Cancer Xenograft Model using [ 18  F]FDG and [ 18  F]FLT PET/CT and MRI

Ziel/Aim In prostate cancer (PC) the development and evaluation of novel targeted therapies play an emerging role potentially improving outcome. Multimodal imaging for therapy response assessment (TRA) of these new drugs is a promising tool to evaluate efficacy. Herein we evaluate the in-vivo efficacy of the indolylmaleimide PDA-66 using small animal F-18 FDG, F-18 FLT PET/CT and MRI in a PC-3 human PC xenograft mouse model. Anti-tumoral effects of PDA-66 were demonstrated in-vitro previously.